Evaluating Cannabis Legalization Through Surveillance: A Question-Oriented Framework for Policy, Clinical, and Public Health Indicators

Evaluating Cannabis Legalization Through Surveillance: A Question-Oriented Framework for Policy, Clinical, and Public Health Indicators

ES评分 0

DOI 10.20900/jpbs.20260015
刊名
JPBS
年,卷(期) 2026, 11(5)
作者
作者单位

The Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N 1N4, Canada

摘要
Background: Cannabis legalization has expanded surveillance systems and generated a growing body of information on cannabis markets, patterns of use, and health outcomes. However, surveillance is often interpreted as though individual indicators provide a general assessment of legalization, despite legalization pursuing multiple policy, clinical, and public health objectives. Objective: To examine how well contemporary cannabis surveillance systems measure the outcomes needed to evaluate legalization and commercialization, and to identify priorities for question-oriented surveillance. Methods: This expert narrative review uses a purposive, conceptually driven synthesis of peer-reviewed studies, systematic and narrative reviews, national surveillance reports, policy documents, and consensus reports. Canadian evidence is emphasized and supplemented by evidence from other legalized jurisdictions. Sources were selected for their relevance to major surveillance domains, measurement problems, and policy or clinical questions rather than through an exhaustive systematic search. The synthesis evaluates the fitness of commonly used indicators and data sources for specific policy, clinical, and public health questions. Results: Contemporary surveillance is strongest for monitoring legal-market development, purchasing patterns, prevalence, frequency of use, and selected acute health indicators. Population surveys, retail data, and administrative systems together provide complementary information on market participation and broad patterns of cannabis use. In contrast, pharmacological dose, cumulative exposure, psychiatric morbidity, cannabis use disorder (CUD), chronic health burden, and equity are measured less consistently. Acute outcomes such as poison-centre calls and emergency presentations provide important surveillance signals but require careful interpretation because ascertainment, healthcare utilization, and diagnostic practices influence observed trends. Measures of CUD differ across diagnostic surveys, treatment systems, and administrative databases because they represent different populations and stages of clinical recognition. Across surveillance domains, individual indicators differ in their proximity to policy change, latency, specificity, and permissible inference, and no single outcome can summarize the effects of legalization. Conclusions: Contemporary cannabis surveillance provides a strong foundation for monitoring markets, patterns of use, and selected acute outcomes but is less developed for measuring clinically meaningful exposure, chronic health consequences, and distributional effects. Surveillance should be organized by matching policy questions to appropriate indicators, target populations, data sources, time horizons, and permissible inferences rather than relying on individual measures as overall indicators of legalization. Strengthening dose measurement, validating clinical indicators, improving equity-sensitive reporting, and harmonizing core measures where appropriate would improve the interpretation of cannabis policy outcomes.
Abstract
Background: Cannabis legalization has expanded surveillance systems and generated a growing body of information on cannabis markets, patterns of use, and health outcomes. However, surveillance is often interpreted as though individual indicators provide a general assessment of legalization, despite legalization pursuing multiple policy, clinical, and public health objectives. Objective: To examine how well contemporary cannabis surveillance systems measure the outcomes needed to evaluate legalization and commercialization, and to identify priorities for question-oriented surveillance. Methods: This expert narrative review uses a purposive, conceptually driven synthesis of peer-reviewed studies, systematic and narrative reviews, national surveillance reports, policy documents, and consensus reports. Canadian evidence is emphasized and supplemented by evidence from other legalized jurisdictions. Sources were selected for their relevance to major surveillance domains, measurement problems, and policy or clinical questions rather than through an exhaustive systematic search. The synthesis evaluates the fitness of commonly used indicators and data sources for specific policy, clinical, and public health questions. Results: Contemporary surveillance is strongest for monitoring legal-market development, purchasing patterns, prevalence, frequency of use, and selected acute health indicators. Population surveys, retail data, and administrative systems together provide complementary information on market participation and broad patterns of cannabis use. In contrast, pharmacological dose, cumulative exposure, psychiatric morbidity, cannabis use disorder (CUD), chronic health burden, and equity are measured less consistently. Acute outcomes such as poison-centre calls and emergency presentations provide important surveillance signals but require careful interpretation because ascertainment, healthcare utilization, and diagnostic practices influence observed trends. Measures of CUD differ across diagnostic surveys, treatment systems, and administrative databases because they represent different populations and stages of clinical recognition. Across surveillance domains, individual indicators differ in their proximity to policy change, latency, specificity, and permissible inference, and no single outcome can summarize the effects of legalization. Conclusions: Contemporary cannabis surveillance provides a strong foundation for monitoring markets, patterns of use, and selected acute outcomes but is less developed for measuring clinically meaningful exposure, chronic health consequences, and distributional effects. Surveillance should be organized by matching policy questions to appropriate indicators, target populations, data sources, time horizons, and permissible inferences rather than relying on individual measures as overall indicators of legalization. Strengthening dose measurement, validating clinical indicators, improving equity-sensitive reporting, and harmonizing core measures where appropriate would improve the interpretation of cannabis policy outcomes.
关键词
cannabis; cannabis legalization; surveillance; public health; policy evaluation; cannabis use disorder; epidemiology
KeyWord
cannabis; cannabis legalization; surveillance; public health; policy evaluation; cannabis use disorder; epidemiology
基金项目
页码 -
  • 参考文献
  • 相关文献
  • 引用本文

Anees Bahji. Evaluating Cannabis Legalization Through Surveillance: A Question-Oriented Framework for Policy, Clinical, and Public Health Indicators [J]. Journal of Psychiatry and Brain Science. 2026; 11; (5). - .

  • 文献评论

相关学者

相关机构